In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s 40billionKenvuedeal,andmore.Togetitinyourinbox,subscribehere.gettyThebattlebetweenNovoNordiskandPfizeroverMetsera,athree−year−oldcompanyworkingontreatmentsforobesityanddiabetes,escalatedthisweek.LastThursday,NovoNordiskmadeanunsolicitedbidforMetseravaluedatupto9 billion–nearly 25% higher than Pfizer’s earlier bid for the comp ...